Yașlılarda İlaç- Besin ve İlaç-Hastalık Etkileșmeleri

Abstract

Dünya genelinde beklenen yaşam süresinin uzadığı ve geriatrik popülasyonunun hızla arttığı bildirilmektedir. Yaşla birlikte birçok hastalık sıklığında artış izlenmekte, bu da polifarmasi uygulamalarının artışını beraberinde getirmektedir. Polifarmasi uygulayan yaşlı bireylerde ilaç-besin ve ilaç-hastalık etkileşmeleri sıklıkla görülmektedir. Besinlerle ilaçların biyotransformasyonları ve etkinliklerinin değişebileceği gibi, ilaçlar da farklı besin öğelerinin biyotransformasyonları ve etkinliklerinin değiştirebilir. Diğer taraftan, var olan hastalık ile ilaç kullanımı sonucu hastalık durumunun kötüleşmesi gibi durumlar ortaya çıkabilir ya da ilaç kullanımı sonucu bazı hastalıkların ortaya çıkış sıklığında artış gözlenebilir. Bu derleme kapsamında ilaç-besin ve ilaç-hastalık etkileşmeleri toksikolojik açıdan değerlendirilecektir.

Keywords

• yaşlı,ilaç,etkileşme,gıda,hastalık

Drug-food and drug-disease interactons in the elderly

Abstract

Around the globe, life expectancy is ascending and geriatric population is rapidly increasing. Frequency of several diseases is rising with age and this brings along polypharmacy. Drug-nutrient and drug-disease interactions are often seen in elderly who apply polypharmacy. While nutrients can change the biotransformation and efficacy of drugs, drugs can also alter the biotransformation and efficacy of nutrients. On the other hand, existing disease along with drugs can worsen the course of the disease or drug use can increase the possibility of disease emergence. This review will evaluate drug-nutrient and drug-disease interactions from a toxicological perspective.

Keywords

• elder,drug,interaction,food,disease

References

1. 1. Clark GS, Siebens HC. Geriatric rehabilitation. In: De Lisa J (ed). Physical Medicine and Rehabilitation. 2nd ed. Philadelphia: Lippincott Williams Wilkins, 2005: 1531-60.
2. 2. Türk Halk Sağlığı Kurumu. Yeterli ve Dengeli Beslenme. İnternet Adresi: http://thsk. saglik. gov.tr/yeterli-ve-dengeli-beslenme/757-ya%C5%9Fl%C4%B1l%C4%B1k ta-beslenme. html#sthash. Dv oYoTqY.dpuf. Erişim Tarihi: 16/02/2015.
3. 3. Crome, P. What’s different about older people. Toxicology, 192: 49-54 (2003).
4. 4. Herrlinger C., Klotz U. Drug metabolism and drug interactions in the elderly. Best Practice and Research in Clinical Gastroenterelogy, 15(6), 897-918 (2001).
5. 5. Hanlon J.T., Shimp L.A., Semla T.P. Recent advances in geriatrics: Drug-related problems in the elderly. Annals of Pharmacotherapy, 34(3), 360-5 (2000).
6. 6. Terrell K.M., Heard K., Miller D.K. Prescribing to Older ED Patients. American Journal of Emergency Medicine 24(4), 468-78, (2006).
7. 7. Delafuente, D.J. Understanding and preventing drug interactions in elderly patients. Critical Reviews in Oncology and Hematology, 48(2),133-43, (2003).
8. 8. Ginsberg, G., Hattis, D., Russ, A., Sonawane, B. Pharmacokinetic and pharmacodynamic factors that can affect sensitivity to neurotoxic sequelae in elderly individuals. Environmental Health Perspectives, 113(9),1243-9, (2005).

9. 9. Diaz, J.A. Fiber and riboflavin absorption. Journal of Ameircan Diet Association, 88(7),783,(1988).
10. 10. López, M.A., Martos, F.C. Iron availability: An updated review. International Journal of Food Science and Nutrition, 55(8), 597-606, (2004).
11. 11. Johnson, B.F., Rodin, S.M, Hoch, K., Shekar ,V. The effect of dietary fiber on the bioavailability of digoxin in capsules. Journal of Clinical Pharmacology, 27(7),487-90(1987).
12. 12. Lattimer, J.M., Haub, M.D. Effects of dietary fiber and its components on metabolic health. Nutrients. 2(12), 1266-89, (2010).
13. 13. Breuer, H.W. Review of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetes. International Journal of Clinical Pharmacological Therapy, 41(10):421-40, (2003).
14. 14. Salvatore, T., Giugliano, D. Pharmacokinetic-pharmacodynamic relationships of Acarbose. Clinical Pharmacokinetics, 30(2):94-106, 1996.
15. 15. Hurrell, R.F., Juillerat, M.A., Reddy, M.B., Lynch, S.R., Dassenko, S.A., Cook, J.D. Soy protein, phytate, and iron absorption in humans. American Journal of Clinical Nutrition, 56(3),573-8, (1992).
16. 16. Jussila, J., Mattila, M.J., Takki, S. Drug absorption during lactose-induced intestinal symptoms in patients with selective lactose malabsorption. Annales medicinae experimentalis et biologiae Fenniae, 48(1),33-7, (1970).
17. 17. Lieb, J. Lactose intolerance. New England Journal of Medicine, 302(3), 178, (1980).
18. 18. Hathcock, J.N. Metabolic mechanisms of drug-nutrient interactions. Federation Proceedings, 44(1 Pt 1),124-9, 1985.
19. 19. McElnay, J.C., Smith, G.D., Helling, D.K. A practical guide to interactions involving theophylline kinetics. Drug Intelligence and Clinical Pharmacy, 16(7-8), 533-42, (1982).
20. 20. Khor, S.P., Hsu, A. The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson’s disease. Current Clinical Pharmacology, 2(3):234-43, (2007).
21. 21. Moon, Y.J., Wang, X., Morris, M.E. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicology in Vitro, 20(2),187-210, (2006).
22. 22. Liu, J., Sridhar, J., Foroozesh, M. Cytochrome P450 family 1 inhibitors and structureactivity relationships. Molecules, 18(12), 14470-95, (2013).
23. 23. Arayne, M.S., Sultana, N., Bibi, Z. Grape fruit juice-drug interactions. Pakistanian Journal of Pharmaceutical Sciences, 18(4), 45-57 (2005).
24. 24. Bailey, D.G., Malcolm, J., Arnold, O., Spence, J.D. Grapefruit juice-drug interactions. British Journal of Clinical Pharmacology 46, 101-10, (1998).
25. 25. Greenblatt, D.J., von Moltke, L.L., Harmat,z J.S., Chen, G., Weemhoff, J.L., Jen, C., Kelley, C.J., LeDuc, B.W., Zinny, M.A. Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. Clinical Pharmacological Therapy 74(2), 121-9, (2003).
26. 26. Desmard, M., Hellmann, R., Plantefève, G., Mentec, H. [Severe overdose in vitamin K antagonist secondary to grapefruit juice absorption]. Annales Françaises D’anesthèsie et de Rèanimation, 28(10):897-9, (2009).
27. 27. Ogawa, R., Echizen, H. Clinically significant drug interactions with antacids: an update. Drugs, 71(14),1839-64, (2011).
28. 28. Jankovic, S.M., Dostic, M. Choice of antiepileptic drugs for the elderly: possible drug interactions and adverse effects. Expert Opinion in Drug Metabolism and Toxicology, 8(1),81-91, (2012).
29. 29. Perucca, E. Pharmacokinetic interactions with antiepileptic drugs. Clinical Pharmacokinetics, 7(1),57-84, (1982).
30. 30. Holló, A., Clemens, Z., Lakatos, P. Epilepsy and vitamin D. International Journal of Neuroscience, 124(6), 387-93, (2014).
31. 31. Schmidt ,L.E., Dalhoff, K. Food-drug interactions. Drugs, 62(10), 1481-502, (2002).
32. 32. Pinto, J.T., Rivlin, R.S. Drugs that promote renal excretion of riboflavin. Drug and Nutrient Interactions, 5(3):143-51, (1987).
33. 33. Evans, M.A. Effects of anticonvulsants and methotrexate on calcium disposition. Naunyn Schmiedeberg’s Archieves of Pharmacology, 315(1), 63-7, (1980).
34. 34. Liamis, G., Milionis, H.J., Elisaf, M. A review of drug-induced hypocalcemia. Journal of Bone and Mineral Metabolism 27(6), 635-42, (2009).
35. 35. Hodgkinson, E., Neville-Webbe, H.L., Coleman, R.E. Magnesium depletion in patients receiving cisplatin-based chemotherapy. Clinical Oncology. 18(9), 710-8, (2006).
36. 36. Bays, H.E., Dujovne, C.A. Drug interactions of lipid-altering drugs. Drug Safety 19(5),355- 71, (1998).
37. 37. Raskin, N.H., Fishman, R.A. Pyridoxine-deficiency neuropathy due to hydralazine. New England Journal of Medicine, 273(22), 1182-5, (1965).
38. 38. Yakabowich, M. Prescribe with care. The role of laxatives in the treatment of constipation. Journal of Gerontology Nurse, 16(7), 4-11, (1990).
39. 39. Ryan, M.P., Devane, J., Ryan, M.F., Counihan, T.B. Effects of diuretics on the renal handling of magnesium. Drugs. 28 Suppl 1, 167-81, (1984).
40. 40. Shiga, A., Matsumoto, S., Ueda, H., Shiga, K., Nishina, Y., Watari, H., Horiike, K. A study of the interaction between chlorpromazine and riboflavin binding protein. Journal of Dermatology, 10(5), 461-7, (1983).
41. 41. Roe, D.A. Drug and nutrient interactions in the elderly diabetic. Drug and Nutrient Interactactions, 5(4), 195-203, (1988).
42. 42. Young, R.C., Blass, J.P. Iatrogenic nutritional deficiencies. Annuals Reviews of Nutrition, 2, 201-27 (1982).
43. 43. Self, T.H., Chrisman, C.R., Baciewicz, A.M., Bronze, M.S. Isoniazid drug and food interactions. American Journal of Medical Sciences, 317(5), 304-11, (1999)
44. 44. Favaro, R.M., Silva, H.C., Vannucchi, H. Bioavailability of vitamin A in the rat following ingestion of neomycin sulfate or aluminium hydroxide. International Journal of Vitamin and Nutritional Research, 64(2), 98-103, (1994).
45. 45. Glueck, C.J., Tsang, R.C., Fallat, R.W., Scheel, D. Plasma vitamin A and E levels in children with familial type II hyperlipoproteinemia during therapy with diet and cholestyramine resin. Pediatrics. 54(1), 51-5, (1974).
46. 46. University of Maryland Medical Center. Vitamin C (Ascorbic Acid). İnternet Adresi: http:// umm.edu/health/medical/altmed/supplement/vitamin-c-ascorbic-acid. Erişim Tarihi: 16/02/2015.
47. 47. Meier, C., Kraenzlin, M.E. Antiepileptics and bone health. Therapeutical Advances in Musculoskeletal Diseases, 3(5), 235-43, (2011).
48. 48. Vidailhet, M., Mallet, E., Bocquet, A., Bresson, J.L., Briend, A., Chouraqui, J.P., Darmaun, D., Dupont, C., Frelut, M.L., Ghisolfi, J., Girardet, J.P., Goulet, O., Hankard, R., Rieu, D., Simeoni, U., Turck, D. Comité de nutrition de la Société française de pédiatrie. Vitamin D: still a topical matter in children and adolescents. A position paperby the Committee on Nutrition of the French Society of Paediatrics. Archieves of Pediatrics, 19(3), 316-28, (2012).
49. 49. Venuturupalli, S.R., Sacks, W. Review of new guidelines for the management of glucocorticoid induced osteoporosis. Current Osteoporosis Reports, 11(4), 357-64, (2013).
50. 50. University of Maryland Medical Center. Drugs that Deplete: Vitamin B9 (Folic Acid). İnternet Adresi: http://umm.edu/health/medical/altmed/supplement-depletion-links/ drugs-that-deplete-vitamin-b9-folic-acid. Erişim Tarihi: 16/02/2015.
51. 51. University of Maryland Medical Center. Drugs that Deplete: Vitamin K. İnternet Adresi: http://umm.edu/health/medical/altmed/supplement-depletion-links/drugs-thatdeplete-vitamin-k. Erişim Tarihi: 16/02/2015.
52. 52. Rondot, P., de Recondo, J., Coignet, A., Ziegler, M. Mental disorders in Parkinson’s disease after treatment with L-DOPA. Advances in Neurology, 40:259-69, (1984).
53. 53. de Smet, Y., Ruberg, M., Serdaru, M., Dubois, B., Lhermitte, F., Agid, Y. Confusion, dementia and anticholinergics in Parkinson’s disease. Journal of Neuroloical and Neurosurgical Psychiatry, 45(12), 1161-4, (1982).
54. 54. Davies, D.L., Wilson, G.M. Diuretics: mechanism of action and clinical application. Drugs, 9(3), 178-226, (1975).
55. 55. Ito, H., Abe, M., Mifune, M., Oshikiri, K., Antoku, S., Takeuchi, Y., Togane, M. Hyperuricemia is independently associated with coronary heart disease and renal dysfunction in patients with type 2 diabetes mellitus. PLoS One, 6(11), e27817, (2011).
56. 56. Sica, D.A., Carter, B., Cushman, W., Hamm, L. Thiazide and loop diuretics. Journal of Clinical Hypertension (Greenwich), 13(9), 639-43, (2011).
57. 57. Wolfs, R.C., Grobbee, D.E., Hofman, A., de Jong, P.T. Risk of acute angle-closure glaucoma after diagnostic mydriasis in nonselected subjects: the Rotterdam Study. Investigative Ophthalmology & Visual Science, 38(12):2683-7, (1997).
58. 58. Razeghinejad, M.R., Pro, M.J., Katz, L.J. Non-steroidal drug-induced glaucoma. Eye (Lond). 25(8), 971-80, (2011).
59. 59. Pavlicević, I., Glavaski, M., Rumboldt, M., Rumboldt, Z. Prohypertensive effects of non-steroidal anti-inflammatory drugs are mostly due to vasoconstriction. Collegium antropologicum. 35(3), 817-22, 2011.
60. 60. Kalafutova, S., Juraskova, B., Vlcek, J. The Impact of Combinations of Non-Steroidal AntiInflammatory Drugs and Anti-Hypertensive Agents on Blood Pressure. Advances of Clinical and Experimental Medicine, 23(6), 993-1000, (2014).
61. 61. Spencer, A.P. Digoxin in heart failure. Critical Care Nurse Clinics of North America, 15(4), 447-52, (2003).
62. 62. Barrese, V., Taglialatela, M. New advances in beta-blocker therapy in heart failure. Frontiers in Physiology, 4, 323, (2013).
63. 63. Di Franco, A., Sarullo, F.M., Salerno, Y., Figliozzi, S., Parrinello, R., Di Pasquale, P., Lanza, G.A. Beta-blockers and ivabradine in chronic heart failure: from clinical trials to clinical practice. American Journal of Cardiovascular Drugs, 14(2), 101-10, (2014).
64. 64. Coupland, N., Wilson, S., Nutt, D. Antidepressant drugs and the cardiovascular system: a comparison of tricylics and selective serotonin reuptake inhibitors and their relevance for the treatment of psychiatric patients with cardiovascular problems. Journal of Psychopharmacology, 11(1):83-92, (1997).
65. 65. House, A.A., Silva Oliveira, S., Ronco, C. Anti-inflammatory drugs and the kidney. International Journal of Artificial Organs, 30(12),1042-6, (2007).
66. 66. Narsinghani, T., Sharma, R. Lead optimization on conventional non-steroidal antiinflammatory drugs: an approach to reduce gastrointestinal toxicity. Chemical and Biological Drug Design, 84(1), 1-23, (2014).
67. 67. Minor, D.S., Meyer, A.M., Long, R.C., Butler, K.R. Jr.-Blockers and chronic obstructive pulmonary disease: inappropriate avoidance? Journal of Clinical Hypertension (Greenwich), 15(12), 925-30, (2013).
68. 68. Chapple, C. Antimuscarinics in men with lower urinary tract symptoms suggestive of bladder outlet obstruction due to benign prostatic hyperplasia. Current Opinions in Urology, 20(1), 43-8, (2010).
69. 69. Paravastu, S.C., Mendonca, D.A., da Silva, A. Beta blockers for peripheral arterial disease. European Journal of Vascular and Endovascular Surgery, 38(1), 66-70, (2009).
70. 70. Patten, S.B., Barbui, C. Drug-induced depression: a systematic review to inform clinical practice. Psychotherapy and Psychosomatics, 73(4), 207-15, 2004.
71. 71. Kotlyar, M., Dysken, M., Adson, D.E. Update on drug-induced depression in the elderly. Americal Journal of Geriatric Pharmacotherapy, 3(4), 288-300, (2005).
72. 72. Keller, S., Frishman, W.H. Neuropsychiatric effects of cardiovascular drug therapy. Cardiology Reviews, 11(2), 73-93, (2003).
73. 73. Louis, W.J., Mander, A.G., Dawson, M., O’-Callaghan, C., Conway, E.L. Use of computerized neuropsychological tests (CANTAB) to assess cognitive effects of antihypertensive drugs in the elderly. Cambridge Neuropsychological Test Automated Battery. Journal of Hypertension, 17(12 Pt 2), 1813-9, (1999).
74. 74. Germain, L., Chouinard, G. Treatment of recurrent unipolar major depression with captopril. Biological Psychiatry, 23(6), 637-41, (1988).
75. 75. Quetsch, R.M., Achor, R.W., Litin, E.M., Faucett, R.L. Depressive reactions in hypertensive patients; a comparison of those treated with Rauwolfia and those receiving no specific antihypertensive treatment. Circulation, 19(3), 366–75, (1959).
76. 76. Lemieux, G., Davignon, A., Genest ,J. Depressive states during Rauwolfia therapy for arterial hypertension; a report of 30 cases. Canadian Medical Association Journal, 74(7), 522-6, (1956).
77. 77. Patten, S.B., Love, E.J. Can drugs cause depression? A review of the evidence. Journal of Psychiatry and Neuroscience, 18(3), 92-102, (1993).
78. 78. Stanton, A.V. Calcium channel blockers. The jury is still out on whether they cause heart attacks and suicide. British Medical Journal (BMJ), 316(7143), 1471-3, (1998).
79. 79. Micheli, F., Pardal, M.F., Gatto, M., Torres, M., Paradiso, G., Parera, I.C., Giannaula, R. Flunarizine- and cinnarizine induced extrapyramidal reactions. Neurology, 37(5), 881-884, (1987).
80. 80. Chouza, C., Scaramelli, A., Caamaño, J.L., De Medina, O., Aljanati, R., Romero, S. Parkinsonism, tardive dyskinesia, akathisia, and depression induced by flunarizine. Lancet, 1(8493), 1303-1304, (1986).
81. 81. Grubb, B.P. Digitalis delirium in an elderly woman. Postgraduate Medicine, 81(8), 329-30, (1987).
82. 82. Song, Y.H., Terao, T., Shiraishi, Y., Nakamura, J. Digitalis intoxication misdiagnosed as depression-- revisited. Psychosomatics, 42(4), 369-70, (2001).
83. 83. Dubnow, M.H., Burchell, H.B. A comparison of digitalis intoxication in two separate periods. Annals of Internal Medicine, 62, 56-65, (1965).
84. 84. Wolfe, R.M. Antidepressant withdrawal reactions. American Family Physician, 56(2), 455- 62, (1997).
85. 85. Web Medical Doctor (Web MD). Pamelor (NORTRIPTYLINE HCl). İnternet Adresi: http://www. Webmd.Com/Drugs/2/Drug-1820/Pamelor-Oral/Details. Erişim Tarihi: 16/02/2015.
86. 86. Fiske, A., Wetherell, J.L., Gatz, M. Depression in older adults. Annuals of Reviews of Clinical Psychology, 5, 363-89, (2009).
87. 87. Vega, P., Sweetland, A., Acha, J., Castillo, H., Guerra, D., Smith Fawzi, MC. Psychiatric issues in the management of patients with multidrug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease, 8(6), 749-59, (2004).
88. 88. Bal’tseva, L.B., Mel’nik, G.V., Man’ko, V.P. [The elimination of chemotherapy side effects in pulmonary tuberculosis patients]. Vrachebnoe Delo, 4,71-3, (1990).
89. 89. Johnson, D.A. Drug-induced psychiatric disorders. Drugs, 22(1), 57-69, (1981).
90. 90. Peloquin, C.A., Berning, S.E. Advice on treatment of drug-resistant tuberculosis. American Journal of Health-System Pharmacy, 54(6), 700-1, (1997).
91. 91. Metcalf, B.W. Inhibitors of GABA metabolism. Biochemical Pharmacology, 28(11),1705- 12,(1979).
92. 92. Sharma, G.S., Gupta, P.K., Jain, N.K., Shanker, A., Nanawati, V. Toxic psychosis to isoniazid and ethionamide in a patient with pulmonary tuberculosis. Tubercle, 60(3),171- 2, (1979).
93. 93. Lansdown, F.S., Beran, M., Litwak, T. Psychotoxic reaction during ethionamide therapy. American Reviews in Respiratory Disease, 95(6), 1053-5, (1967).
94. 94. Pickles, R.W., Spelman, D.W. Suspected ethambutol-induced mania. Medical Journal of Australia 164(7), 445-6, (1996).
95. 95. Patel, A.M., McKeon, J. Avoidance and management of adverse reactions to antituberculosis drugs. Drug Safety, 12(1), 1-25, (1995).
96. 96. Feinberg, S.S. Fluoroquinolone-induced depression. American Journal of Psychiatry, 152(6), 954-5, (1995).
97. 97. Jay, G.T., Fitzgerald, J.M. Ciprofloxacin-induced delirium. Annals of Pharmacotherapy 31(2):252, (1997).
98. 98. Zaudig, M., von Bose, M., Weber, M.M., Bremer, D., Zieglgänsberger, W. Psychotoxic effects of ofloxacin. Pharmacopsychiatry, 22(1), 11-5, (1989).
99. 99. Sirota, R.A., Kimmel, P.L., Trichtinger, M.D., Diamond, B.F., Stein, H.D., Yudis, M. Metoclopramide-induced parkinsonism in hemodialysis patients. Report of two cases. Archieves of Internal Medicine, 146(10), 2070-2071, (1986).
100. 100. Grimes, J.D., Hassan, M.N., Krelina, M. Long-term followup of tardive dyskinesia due to metoclopramide. Lancet, 2(8297), 563, (1982).
101. 101. Meyer, J.S. Biochemical effects of corticosteroids on neural tissues. Physiology Reviews, 65(4), 946-1020, (1985).
102. 102. De Kloet, E.R., Sutanto, W., Rots, N., van Haarst, A., van den Berg, D., Oitzl, M. Plasticity and function of brain corticosteroid receptors during aging. Acta Endocrinologica (Copenh) 125(Suppl 1), 65-72, (1991).
103. 103. Pavlides,, C., Watanab,e Y., McEwen, B.S. Effects of glucocorticoids on hippocampal longterm potentiation. Hippocampus 3(2), 183-92, (1993).
104. 104. Cerullo, M.A. Expect psychiatric side effects from corticosteroid use in the elderly. Geriatrics 63(1), 15-8, (2008).
105. 105. Brody S. Psychiatric observations in patients treated with cortisone and ACTH. Psychosomatic Medicine, 14(2), 94-103, (1952).
106. 106. Lewis, D.A., Smith, R.A. Steroid induced psychiatric symptoms. Journal of Affective Disorders, 5(4), 319-32, (1983).
107. 107. McEwen, B.S., de Leon, M.J., Lupien, S.J., Meaney, M.J. Corticosteroids, the aging brain and cognition. Trends in Endocrinology Metabolism 10(3), 92-6, (1999).
108. 108. Mitchell AJ, Dening TR. Depression-related cognitive impairment: possibilities for its pharmacological treatment. Journal of Affective Disorders, 36(3-4), 79-87, (1996).
109. 109. Jamora, D., Lim, S.H., Pan, A., Tan, L., Tan, E.K. Valproate induced Parkinsonism in epilepsy patients. Movement Disorders, 22(1),130-3, (2007).
110. 110. Zadikoff, C, Munhoz, R.P., Asante, A.N., Politzer, N., Wennberg, R., Carlen, P., Lang, A. Movement disorders in patients taking anticonvulsants. J Neurol Neurosurg Psychiatry 2007;78(2):147-51.
111. 111. Morgan, J.C., Kapil, D.S. Drug-induced tremors. Lancet Neurology, 4(12), 866–76, (2005).
112. 112. Henry, C. Lithium side-effects and predictors of hypothyroidism in patients with bipolar disorder: Sex differences. Journal of Psychiatry and Neuroscience, 27:104–7, (2002).
113. 113. Vestergaard, P., Poulstrup, I., Shou, M. Prospective studies on a lithium cohort 3. Tremor, weight gain, diarrhea, psychological complains. Acta Psychiatrica Scandinavica,78:434–41,(1988).
114. 114. Carroll, J.A., Jefferson, J.W., Greist, J.H. Treating tremor induced by lithium. Hospital Community Psychiatry 38, 1280–8 (1987).
115. 115. Xydakis, A.M., Jones, PH. Toxicity of antilipidemic agents: facts and fictions. Current Atherosclerosis Reports 5(5), 403-10, (2003).
116. 116. Gupta, A., Guyomard, V., Zaman, M.J., Rehman, H.U., Myint, P.K. Systematic review on evidence of the effectiveness of cholesterol lowering drugs. Advances in Therapy 27(6),348- 64, (2010).
117. 117. Chen, Z., Peto, R., Collins, R., MacMahon, S., Lu, J., Li, W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. British Medical Journal, 303(6797), 276-82, (1991).
118. 118. Haag, M. Essential fatty acids and the brain. Canadian Journal of Psychiatry, 48(3),195- 203,(2003).
119. 119. Manfredi, G., Beal, M.F. The role of mitochondria in the pathogenesis of neurodegenerative diseases. Brain Pathology, 10(3), 462-72, (2000).
120. 120. Murphy, J.M., Monson, R.R., Olivier, D.C., Sobol, A.M., Pratt, L.A., Leighton, A.H. Mortality risk and psychiatric disorders. Results of a general physician survey. Social Psychiatry and Psychiatric Epidemiology, 24(3), 134-42, 1989.
121. 121. Brown, S.L., Salive, M.E., Harris, T.B., Simonsick, E.M., Guralnik, J.M., Kohout, F.J. Low cholesterol concentrations and severe depressive symptoms in elderly people. British Medical Journal 308(6940), 1328-32, (1994).
122. 122. Rothermich, N.O. An extended study of indomethacin. II. Clinical therapy. Journal of the American Medical Association (JAMA), 195(13), 1102-6, (1966).
123. 123. Thompson, M., Percy, J.S. Further experience with indomethacin in the treatment of rheumatic disorders. British Medical Journal, 1(5479), 80-3, (1966).
124. 124. Carney, M.W. Paranoid psychosis with indomethacin. British Medical Journal, 2(6093), 994-5, (1977).
125. 125. Gotz, V. Paranoid psychosis with indomethacin. British Medical Journal, 1(6104), 49, (1978).
126. 126. Browning, C.H. Nonsteroidal anti-inflammatory drugs and severe psychiatric side effects. International Journal of Psychiatry Medicine 26(1), 25-34, (1996).
127. 127. Jiang, H.K., Chang, D.M. Non-steroidal anti-inflammatory drugs with adverse psychiatric reactions: five case reports. Clinical Rheumatology, 18(4), 339-45, (1999).
128. 128. Sax, M.J. Clinically important adverse effects and drug interactions with H2-receptor antagonists: an update. Pharmacotherapy, 7(6Pt 2), 110S-115S, (1987).
129. 129. Totte, J., Scharpe, S., Verkerk, R., Neels, H., Vanhaeverbeek, M., Smitz, S., Rousseau, J.J. Neurological dysfunction associated with abnormal levels of cimetidine metabolite. Lancet, 1(8228), 1047, (1981).
130. 130. Russell, W.L., Lopez, L.M. Cimetidine-induced mental status changes: case report and literatüre review. American Journal of Hospital Pharmacy 37(12), 1667-71, (1980).
131. 131. Billings, R.F., Tang, S.W., Rakoff, V.M. Depression associated with cimetidine. Canadian Journal of Psychiatry, 26(4), 260-1, (1981).
132. 132. Billings, R.F., Stein, M.B. Depression associated with ranitidine. American Journal of Psychiatry 143(7), 915-6, (1986).
133. 133. Robins, A.H., Lucke, W., McFadyen, M.L., Wright, J.P. Effect of the H2-receptor antagonist ranitidine on depression and anxiety in duodenal ulcer patients. Postgraduate Medical Journal, 60(703), 353-5, (1984).
134. 134. Seeman, P. Atypical antipsychotics: mechanism of action. Canadian Journal of Psychiatry, 47(1), 27-38, (2002).
135. 135. Tarsy, D., Baldessarini, R.J., Tarazi, F.I. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs, 16(1), 23-45, (2002).